Patch International Inc.

Pharma company's Aridol phase III trial achieved endpoints

Published in Nursing Home and Elder Business Week, November 28th, 2004

Patch International Inc. (PAII: OTCBB, PQG: Berlin Bremen Stock Exchange) said that Pharmaxis (PXS: Australian Stock Exchange) announced that the phase III clinical trial of Aridol achieved its endpoints.

The trial was designed to evaluate Aridol as a test for asthma. The positive results mean the company will apply for marketing authorization later this year in Australia, and early in 2005 in Europe. Subject to regulatory approval, sales of Aridol are expected to commence in 2005. The annual revenue potential of Aridol as a management tool for Asthma is estimated to be in excess of $250 million. Patch holds 11.2 million shares in Pharmaxis and is the company's second...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Nursing Home and Elder Business Week

Source: Nursing Home and Elder Business Week (2004-11-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry